Inhibikase Therapeutics, Inc. (IKT)
|Net Income (ttm)||-4.53M|
|Trading Day||January 25|
|Day's Range||6.57 - 6.86|
|52-Week Range||6.53 - 9.90|
Inhibikase Therapeutics Announces Partnership with Clintrex Research Corporation; C. Warren Olanow, MD, to Serve as Interim Chief Medical Officer
ATLANTA, Jan. 4, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and rela...
ATLANTA, Dec. 28, 2020 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase"), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and r...
/PRNewswire/ -- Inhibikase Therapeutics, Inc. (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related...
Eight SPACs went public this past week but no IPOs, as all three scheduled deals postponed or withdrew. New filing activity picked up, led by long-awaited delivery service unicorn DoorDash (DA...
Neurodegenerative disease biotech Inhibikase Therapeutics lowers proposed deal size by 40% ahead of $15 million IPO
Inhibikase Therapeutics, a clinical stage biotech developing kinase inhibitors for Parkinson's and related disorders, lowered the proposed deal size for its upcoming IPO on Tuesday. The Atlant...
Inhibikase Files Registration Statement for Proposed Initial Public Offering - read this article along with other careers information, tips and advice on BioSpace
Inhibikase Therapeutics, a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease, and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a c-Abl protein kinase inhibitor for use in the treatment of Parkinson's Disease, dysphagia, and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. It offers products comprise IkT-01427, a product candidate... [Read more...]
|IPO Date |
Dec 23, 2020
Milton H. Werner
|Stock Exchange |
|Ticker Symbol |
In 2019, IKT's revenue was $1.12 million, a decrease of -72.22% compared to the previous year's $4.04 million. Losses were -$5.72 million, 165.9% more than in 2018.